🇺🇸 FDA
Patent

US 7670806

ADP-ribosyl acceptor hydrolase 3 (ARH3) polypeptides and methods of use

granted A61PA61P43/00

Quick answer

US patent 7670806 (ADP-ribosyl acceptor hydrolase 3 (ARH3) polypeptides and methods of use) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Feb 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Mar 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P43/00